Last reviewed · How we verify
NCT04808596: PHBR
Pulmonary Hypertension Biorepository and Registry
trial in Pulmonary Hypertension in 300 participants. Currently enrolling.
31 December 2026
Quick facts
| Lead sponsor | University of Kansas Medical Center |
|---|---|
| Status | Recruiting now |
| Study type | OBSERVATIONAL |
| Enrollment | 300 |
| Start date | 10 August 2020 |
| Primary completion | 31 December 2026 |
| Estimated completion | 31 July 2027 |
| Sites | 1 location across United States |
Conditions studied
- Pulmonary Hypertension — all drugs for Pulmonary Hypertension →
- Pulmonary Arterial Hypertension — all drugs for Pulmonary Arterial Hypertension →
- Pulmonary Hypertension Due to Left Heart Disease — all drugs for Pulmonary Hypertension Due to Left Heart Disease →
- Pulmonary Hypertension, Primary — all drugs for Pulmonary Hypertension, Primary →
Sponsor
University of Kansas Medical Center
Who can join
18 and older, any sex, with Pulmonary Hypertension or Pulmonary Arterial Hypertension. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
Establish a pulmonary hypertension registry and biorepository to lead towards a further understanding of the disease.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT04808596
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Pulmonary Hypertension
Currently open trials in the same condition.
- NCT07179380 — Efficacy and Safety Study of Treprostinil Palmitil Inhalation Powder (TPIP) in Participants With Pulmonary Hypertension · Phase 3 · recruiting
- NCT07073820 — A Study to Learn About the Study Medicine (Called PF-07868489) in People With Pulmonary Arterial Hypertension Who Have P · Phase 2 · recruiting
- NCT06351345 — 129 Xenon Imaging in Patients Treated With Sotatercept · Phase 2 · recruiting
- NCT07187206 — Safety and Efficacy of FETO in CDH Phase III · Phase 3 · recruiting
- NCT07206173 — Londrina Activities of Daily Living Protocol in Pulmonary Hypertension · recruiting
Other University of Kansas Medical Center trials
Trials by the same sponsor.
- NCT06636214 — Adapting Changing Talk: Online (CHATO) to CHATO-Inclusive · NA · not yet recruiting
- NCT07528963 — KanSurvive 2.0: Testing Enhanced Models of Cancer Survivorship Care for Rural Cancer Survivors in Primary Care Practice · NA · enrolling by invitation
- NCT07463755 — Low-Fidelity Driving Simulator Training in Parkinson's Disease. · NA · not yet recruiting
- NCT07420621 — Preliminary Effectiveness of Enhanced Text Message + Incentives · NA · recruiting
- NCT07491510 — Improving Prenatal Care to Reduce Early Onset Preeclampsia in Low-Income · NA · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT04808596 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by University of Kansas Medical Center
- Last refreshed: 1 August 2025
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04808596.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing